Last checked at 10 Apr 2019 11:52
10 April 2019
N4 Pharma Plc
("N4 Pharma" or the "Company")
Director/PDMR shareholding
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments, announces that Nigel Theobald, Chief Executive Officer of the Company, has purchased 67,343 ordinary shares in the Company ("Ordinary Shares") at a price of 4.44 pence per Ordinary Share. In addition, Anne-Marie Lawrence, wife of Nigel Theobald and a person closely associated with him, has today purchased 67,343 Ordinary Shares at a price of 4.44 pence per Ordinary Share.
As a result of these purchases, Nigel Theobald's interest in the Company is now 16,981,319 Ordinary Shares, which represents approximately 16.74 per cent. of Company's issued share capital.
Enquiries:
N4 Pharma Plc Nigel Theobald, CEO |
Via Alma PR
|
Allenby Capital Limited James Reeve/Asha Chotai
| Tel: +44(0)203 328 5656 |
Scott PR Georgia Smith | Tel: +44(0)1477 539 539 |
About N4 Pharma plc
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
a)
| Name | Nigel Theobald | ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Chief Executive Officer | ||||
b)
| Initial notification /Amendment | Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a)
| Name
| N4 Pharma PLC | ||||
b)
| LEI
| 213800I841D2RKMFK955 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)
| Description of the financial instrument, type of instrument Identification code | Ordinary shares of 0.4p
GB00BYW8QM32 | ||||
b)
| Nature of the transaction
| Purchase of ordinary shares in the Company | ||||
c)
| Price(s) and volume(s) |
| ||||
d)
| Aggregated information - Aggregated volume - Price
| Aggregated volume: 67,343 Weighted average price: 4.44 pence per share | ||||
e)
| Date of the transaction | 10 April 2019 | ||||
f)
| Place of the transaction
| London Stock Exchange, XLON | ||||
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
a)
| Name | Anne-Marie Lawrence | ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Wife and PCA of Chief Executive Officer | ||||
b)
| Initial notification /Amendment | Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a)
| Name
| N4 Pharma PLC | ||||
b)
| LEI
| 213800I841D2RKMFK955 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)
| Description of the financial instrument, type of instrument Identification code | Ordinary shares of 0.4p
GB00BYW8QM32 | ||||
b)
| Nature of the transaction
| Purchase of ordinary shares in the Company | ||||
c)
| Price(s) and volume(s) |
| ||||
d)
| Aggregated information - Aggregated volume - Price
| Aggregated volume: 67,343 Weighted average price: 4.44 pence per share | ||||
e)
| Date of the transaction | 10 April 2019 | ||||
f)
| Place of the transaction
| London Stock Exchange, XLON | ||||